Navigation Links
Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Date:7/25/2012

A funding and the initiation of our Company's operations in late 2010.  This is the first oral SINE to ever enter human studies, and we are eager to assess the potential of our drug candidate across a wide variety of cancers."

The study is being conducted in the United States, Toronto, Canada, and Copenhagen, Denmark. NPM Pharma (Canada) is overseeing the trial on behalf of Karyopharm.

About Karyopharm

Karyopharm is a biopharmaceutical company leading the development of small molecule modulators of nuclear transport.  The Company was founded by Drs. Sharon Shacham and Michael Kauffman in 2008.  Karyopharm has raised approximately $34M since its inception and has won several grants/awards including a Biotech Investment Award by the Multiple Myeloma Research Foundation in 2010. Karyopharm's first program is directed towards the Selective Inhibition of Nuclear Export – its SINE program – targeting CRM1, the major nuclear export protein. SINE compounds, including KPT-330 and KPT-335, force the activation of the cell's key tumor suppressor proteins and anti-inflammatory pathways including p53, p21, pRB, FoxO, and IkB, a key cellular inhibitor of nuclear factor NF-kB. Karyopharm is currently evaluating two oral SINE compounds in clinical trials. KPT-330 oral is being evaluated in patients with cancer, and KPT-335 oral is being studied in dogs with relapsed/refractory non-Hodgkin's Lymphomas.  The Company is also evaluating the use of SINEs in autoimmune/inflammatory disorders, viral infections and dermatologic diseases. Karyopharm Therapeutics is located in Natick, Massachusetts.

contact: Michael Kauffman, 508-975-4821, mkauffman@karyopharm.com   

 


'/>"/>
SOURCE Karyopharm Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. PTC Therapeutics Closes $30 Million Financing
3. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
4. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
5. Echo Therapeutics Expands License Agreement with Ferndale Pharma
6. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
7. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
8. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
9. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
10. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
11. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... LAS VEGAS , March 26, 2015 /PRNewswire/ ... worldwide sales agreement with Radlink, Inc., an emerging ... offer real-time image guidance with its hip replacement ... ongoing commitment to help improve patient outcomes, increase ... in conjunction with the 81st annual meeting of ...
(Date:3/26/2015)... 26, 2015  Oxis Biotech, Inc. (OXIS), ... Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] ... option agreement with the University of Pittsburgh ... Dr. Xiang-Qun Xie , Associate Dean ... School of Pharmacy.  These patents/intellectual properties relate ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
Breaking Medicine Technology:DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 3Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2
(Date:3/26/2015)... “The SWEET Act is an important step ... available and help parents who are working to reduce sugar ... approach to support public health, and we will continue to ... health of all families,” said Dr. Jane Delgado President and ... introduction of the Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman ...
(Date:3/26/2015)... 26, 2015 The Life Support ... to Hyperbaric Medicine” course, which is accredited by ... and the National Board of Diving & Hyperbaric ... course 4 times a year at several of ... tri-state region; registration is available on-line at: ...
(Date:3/26/2015)... The National League for Nursing, and ... has announced its partnership with Questionmark®, a supplier ... to accurately and securely measure knowledge, skills, and ... Questionmark’s state-of-the-art software and a custom-built portal, ... of the seventy-five to one hundred thousand exams ...
(Date:3/26/2015)... 26, 2015 In preparation for the ... Revolution, founded by Samir Becic, has issued “report ... personal health and fitness, as well as their promotion ... list includes Sen. Ted Cruz, who has officially announced ... all other politicians who have shown interest in running ...
(Date:3/26/2015)... 26, 2015 Zane Benefits, the leader ... a new eBook, “The Comprehensive Guide To Interviewing For ... is the most important aspect of the hiring process. ... hiring the right way, possibly resulting in thousands of ... arduous undertaking, yet it’s essential to the success of ...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:NLN Testing Services Announces Improved Delivery and Analytics Software and Newly Developed and Revised Exams 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:Zane Benefits Announces: New eBook: The Comprehensive Guide To Interviewing For Your Small Business 2
... Orthopedic,Group, Inc. (NYSE: HGR ) announces record revenue ... $0.18 per diluted share, for the quarter ended,September 30, ... increase in,net sales, a 24.6% increase in net income, ... pro-forma results for the third quarter of 2006. The,pro-forma ...
... the inaugural Mississippi Blues Marathon and,Half-Marathon, scheduled for January 5, 2008. Prize money will be awarded,in the following categories ... Male Female 1st Place $4,000 ... 3,000 3rd Place 2,000 2,000 4th ... 1,000 1,000, Wheelchair $500 ...
... Md., Oct. 29 The Cystic Fibrosis,Foundation was selected ... USA Track & Field (USATF), the national governing body ... The CF Foundation was honored for its largest fundraising ... nearly $32 million in 2006,and for other road races, ...
... are diagnosed with breast cancer at a younger age ... than Caucasian women, a Yale School of Medicine researcher ... Therapeutic Radiology and Oncology meeting in Los Angeles, ... Yale Cancer Center member, said her results were based ...
... important new research on the topics of cardiovascular ... kidney injury, racial and ethnic disparities of kidney ... being presented during the American Society of Nephrology,s ... Francisco at a policy-centered news briefing on Saturday, ...
... small, short-term trial is unlikely to quiet Natrecor,s critics , , ... the safety of Natrecor, a widely used heart failure medication, ... , Critics have charged that Natrecor, which costs about $500 ... may raise their risk of kidney failure and death. , ...
Cached Medicine News:Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 2Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 3Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 4Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 5Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 6Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 7Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 8Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 9Health News:Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field 2Health News:Breast cancer is more aggressive in African-American women 2Health News:Study Supports Controversial Heart Failure Drug 2Health News:Study Supports Controversial Heart Failure Drug 3Health News:Study Supports Controversial Heart Failure Drug 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: